Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
iShares Genomics Immunology and Healthcare ETF ETF · iShares Trust
63 holdings · as of 2026-04-30 (4.6 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 120% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT 31.77% of portfolio weight is in non-compliant holdings, over the 5% threshold.
63 holdings, 43 matched (72% of weight). Portfolio as of 2026-04-30, filed 2026-06-25. Source: SEC Form N-PORT.
6.03% of this portfolio’s income is non-permissible — weighted across holdings, computed over 67% of portfolio weight (38 of 63 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
45.8% compliant 0.0% questionable 26.4% non-compliant 27.8% unscreened
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | UNSCREENED | 20.98% | no in-house ratios for this holding |
| REVOLUTION MEDICINES, INC. | UNSCREENED | 6.85% | no in-house ratios for this holding |
| MRNA MODERNA, INC. | NON_COMPLIANT | 6.28% | AAOIFI2.2% Usmani11.7% Dow Jones Islamic7.4% S&P Shariah5.1% MSCI Islamic11.4% MSCI Islamic M-Series5.1% FTSE Shariah5.4% |
| IPN.PA IPSEN SA | COMPLIANT | 5.24% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahpass |
| BAYN.DE Bayer Aktiengesellschaft | NON_COMPLIANT | 4.38% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| 4502.T Takeda Pharmaceutical Company Limited | NON_COMPLIANT | 4.22% | AAOIFIfail Usmanipass Dow Jones Islamicfail S&P Shariahfail MSCI Islamicpass MSCI Islamic M-Seriesfail FTSE Shariahpass |
| MRK MERCK & CO., INC. | COMPLIANT | 4.15% | AAOIFI14.7% Usmani41.5% Dow Jones Islamic21.8% S&P Shariah20.9% MSCI Islamic41.5% MSCI Islamic M-Series20.9% FTSE Shariah41.5% |
| GSK GSK PLC | COMPLIANT | 4.12% | AAOIFI19.2% Usmani23.6% Dow Jones Islamic10.6% S&P Shariah11.2% MSCI Islamic23.6% MSCI Islamic M-Series11.2% FTSE Shariah23.6% |
| 22UA.DE BioNTech SE | NON_COMPLIANT | 4.07% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| RO.SW Roche Holding AG | COMPLIANT | 3.99% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| EXEL EXELIXIS, INC. | COMPLIANT | 3.80% | AAOIFI1.2% Usmani6.7% Dow Jones Islamic1.5% S&P Shariah1.7% MSCI Islamic6.7% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| TWST Twist Bioscience Corp | COMPLIANT | 3.79% | AAOIFI1.1% Usmani13.9% Dow Jones Islamic3.2% S&P Shariah3.5% MSCI Islamic13.9% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| REGN REGENERON PHARMACEUTICALS, INC. | COMPLIANT | 3.73% | AAOIFI2.4% Usmani6.5% Dow Jones Islamic3.0% S&P Shariah2.7% MSCI Islamic4.8% MSCI Islamic M-Series2.7% FTSE Shariah4.8% |
| SNY SANOFI SA | COMPLIANT | 3.58% | AAOIFI20.8% Usmani14.7% Dow Jones Islamic38.1% S&P Shariah38.6% MSCI Islamic14.7% MSCI Islamic M-Series38.6% FTSE Shariah14.7% |
| VRTX VERTEX PHARMACEUTICALS INCORPORATED | COMPLIANT | 3.55% | AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| INCY INCYTE CORPORATION | COMPLIANT | 3.52% | AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.3% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| GMAB.CO GENMAB A/S | COMPLIANT | 3.16% | AAOIFIpass Usmanifail Dow Jones Islamicfail S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| IDYA IDEAYA Biosciences Inc | COMPLIANT | 2.71% | AAOIFI0.8% Usmani2.2% Dow Jones Islamic1.2% S&P Shariah1.2% MSCI Islamic2.2% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| Immunitybio Inc | UNSCREENED | 2.61% | no in-house ratios for this holding |
| CAI CARIS LIFE SCIENCES, INC. | COMPLIANT | 2.44% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| RCUS ARCUS BIOSCIENCES, INC. | COMPLIANT | 2.12% | AAOIFI3.0% Usmani12.3% Dow Jones Islamic5.9% S&P Shariah6.5% MSCI Islamic12.3% MSCI Islamic M-Series6.5% FTSE Shariah10.9% |
| 4528.T ONO PHARMACEUTICAL CO., LTD. | COMPLIANT | 1.86% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahpass |
| CRSP CRISPR Therapeutics AG | NON_COMPLIANT | 1.80% | AAOIFI15.5% Usmani29.6% Dow Jones Islamic17.0% S&P Shariah16.8% MSCI Islamic29.6% MSCI Islamic M-Series16.8% FTSE Shariah22.1% |
| NVAX NOVAVAX, INC. | NON_COMPLIANT | 1.31% | AAOIFI17.3% Usmani31.1% Dow Jones Islamic21.2% S&P Shariah22.9% MSCI Islamic30.5% MSCI Islamic M-Series22.9% FTSE Shariah30.5% |
| IOVA Iovance Biotherapeutics Inc | COMPLIANT | 1.24% | AAOIFI1.2% Usmani5.0% Dow Jones Islamic2.9% S&P Shariah2.4% MSCI Islamic5.0% MSCI Islamic M-Series2.4% FTSE Shariah0.0% |
| 2595.HK GenFleet Therapeutics (Shanghai) Inc | NON_COMPLIANT | 1.20% | AAOIFI0.9% Usmani5.4% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic4.6% MSCI Islamic M-Seriesfail FTSE Shariah4.6% |
| NUVB Nuvation Bio Inc | NON_COMPLIANT | 1.18% | AAOIFI10.5% Usmani33.9% Dow Jones Islamic18.7% S&P Shariah23.6% MSCI Islamic33.9% MSCI Islamic M-Series23.6% FTSE Shariah33.4% |
| VIR Vir Biotechnology Inc | NON_COMPLIANT | 1.07% | AAOIFI6.1% Usmani7.7% Dow Jones Islamic8.6% S&P Shariah8.1% MSCI Islamic7.7% MSCI Islamic M-Series8.1% FTSE Shariah0.0% |
| ABCL ABCELLERA BIOLOGICS INC. | NON_COMPLIANT | 1.06% | AAOIFI3.8% Usmani10.4% Dow Jones Islamic11.0% S&P Shariah11.0% MSCI Islamic10.4% MSCI Islamic M-Series11.0% FTSE Shariah0.0% |
| CRVS Corvus Pharmaceuticals Inc | COMPLIANT | 0.97% | AAOIFI0.1% Usmani0.3% Dow Jones Islamic0.1% S&P Shariah0.2% MSCI Islamic0.3% MSCI Islamic M-Series0.2% FTSE Shariah0.0% |
| JANX Janux Therapeutics Inc | NON_COMPLIANT | 0.86% | AAOIFI1.7% Usmani2.1% Dow Jones Islamic1.4% S&P Shariah1.4% MSCI Islamic2.1% MSCI Islamic M-Series1.4% FTSE Shariah0.0% |
| Kura Oncology Inc | UNSCREENED | 0.83% | no in-house ratios for this holding |
| Sunshine Lake Pharma Co Ltd | UNSCREENED | 0.62% | no in-house ratios for this holding |
| CTMX CytomX Therapeutics Inc | NON_COMPLIANT | 0.60% | AAOIFI0.7% Usmani1.5% Dow Jones Islamic1.3% S&P Shariah1.8% MSCI Islamic1.5% MSCI Islamic M-Series1.8% FTSE Shariah0.0% |
| OCGN Ocugen Inc | NON_COMPLIANT | 0.59% | AAOIFI1.2% Usmani4.5% Dow Jones Islamic1.5% S&P Shariah1.7% MSCI Islamic4.5% MSCI Islamic M-Series1.7% FTSE Shariah1.4% |
| RIGL RIGEL PHARMACEUTICALS, INC. | COMPLIANT | 0.57% | AAOIFI5.0% Usmani8.8% Dow Jones Islamic9.0% S&P Shariah11.3% MSCI Islamic8.8% MSCI Islamic M-Series11.3% FTSE Shariah8.6% |
| AbClon Inc. | UNSCREENED | 0.56% | no in-house ratios for this holding |
| NTLA INTELLIA THERAPEUTICS, INC. | NON_COMPLIANT | 0.56% | AAOIFI4.1% Usmani8.6% Dow Jones Islamic5.1% S&P Shariah4.1% MSCI Islamic8.6% MSCI Islamic M-Series4.1% FTSE Shariah0.0% |
| 2696.HK Shanghai Henlius Biotech Inc | COMPLIANT | 0.50% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | NON_COMPLIANT | 0.48% | AAOIFI168.3% Usmani93.9% Dow Jones Islamic143.6% S&P Shariah79.6% MSCI Islamic93.9% MSCI Islamic M-Series79.6% FTSE Shariah85.7% |
| Design Therapeutics Inc | UNSCREENED | 0.47% | no in-house ratios for this holding |
| VLA.PA VALNEVA SE | NON_COMPLIANT | 0.44% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| DNA Ginkgo Bioworks Holdings Inc | NON_COMPLIANT | 0.40% | AAOIFI86.3% Usmani40.8% Dow Jones Islamic70.5% S&P Shariah31.1% MSCI Islamic40.8% MSCI Islamic M-Series31.1% FTSE Shariah0.0% |
| VSTM VERASTEM, INC. | NON_COMPLIANT | 0.40% | AAOIFI6.3% Usmani16.1% Dow Jones Islamic8.5% S&P Shariah10.1% MSCI Islamic16.1% MSCI Islamic M-Series10.1% FTSE Shariah14.8% |
| ALVO Alvotech SA | NON_COMPLIANT | 0.39% | AAOIFI61.2% Usmani87.4% Dow Jones Islamic56.2% S&P Shariah50.1% MSCI Islamic87.4% MSCI Islamic M-Series50.1% FTSE Shariah87.4% |
| PSNL Personalis Inc | NON_COMPLIANT | 0.33% | AAOIFI2.0% Usmani11.9% Dow Jones Islamic5.7% S&P Shariah8.0% MSCI Islamic11.9% MSCI Islamic M-Series8.0% FTSE Shariah0.0% |
| Xencor Inc | UNSCREENED | 0.30% | no in-house ratios for this holding |
| Guangzhou Innogen Pharmaceutical Group Co Ltd | UNSCREENED | 0.13% | no in-house ratios for this holding |
| PRME Prime Medicine Inc | NON_COMPLIANT | 0.13% | AAOIFI16.8% Usmani45.2% Dow Jones Islamic21.9% S&P Shariah18.8% MSCI Islamic45.2% MSCI Islamic M-Series18.8% FTSE Shariah0.0% |
| EURO | UNSCREENED | 0.04% | no in-house ratios for this holding |
| MREO Mereo BioPharma Group PLC | NON_COMPLIANT | 0.04% | AAOIFI2.6% Usmani3.0% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic3.0% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| GREAT BRITISH POUND | UNSCREENED | 0.01% | no in-house ratios for this holding |
| SWISS FRANC | UNSCREENED | 0.00% | no in-house ratios for this holding |
| DANISH KRONER | UNSCREENED | 0.00% | no in-house ratios for this holding |
| ARCELLX INC CVR | UNSCREENED | 0.00% | no in-house ratios for this holding |
| XAV HEALTH CARE JUN26 | UNSCREENED | 0.00% | no in-house ratios for this holding |
| JAPANESE YEN | UNSCREENED | 0.00% | no in-house ratios for this holding |
| HONG KONG DOLLAR | UNSCREENED | 0.00% | no in-house ratios for this holding |
| NEW TAIWAN DOLLAR | UNSCREENED | 0.00% | no in-house ratios for this holding |
| KOREAN WON | UNSCREENED | 0.00% | no in-house ratios for this holding |
| BlackRock Funds III: BlackRock Cash Funds: Treasury; SL Agency Shares | UNSCREENED | 0.00% | no in-house ratios for this holding |
| OABI OMNIAB INC | NON_COMPLIANT | 0.00% | AAOIFI3.0% Usmani6.5% Dow Jones Islamic5.9% S&P Shariah4.7% MSCI Islamic6.5% MSCI Islamic M-Series4.7% FTSE Shariah0.0% |
| OABI OMNIAB INC | NON_COMPLIANT | 0.00% | AAOIFI3.0% Usmani6.5% Dow Jones Islamic5.9% S&P Shariah4.7% MSCI Islamic6.5% MSCI Islamic M-Series4.7% FTSE Shariah0.0% |
The published standards disagree about this fund by 25 points of portfolio weight — 44.4% of it passes AAOIFI, 19.1% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 44.4% ratios fail on 35.5% 40.4% not rated under AAOIFI
ratios pass on 26.0% ratios fail on 53.9% 40.4% not rated under Usmani
ratios pass on 34.9% ratios fail on 44.9% 40.4% not rated under Dow Jones Islamic
ratios pass on 38.1% ratios fail on 39.0% 43.1% not rated under S&P Shariah
ratios pass on 19.1% ratios fail on 64.3% 36.8% not rated under MSCI Islamic
ratios pass on 38.1% ratios fail on 39.0% 43.1% not rated under MSCI Islamic M-Series
ratios pass on 31.2% ratios fail on 48.6% 40.4% not rated under FTSE Shariah
42 of 63 listed holdings carry our own per-methodology verdicts (87% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 32 (57% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| MRNA MODERNA, INC. | 6.28% |
| BAYN.DE Bayer Aktiengesellschaft | 4.38% |
| 4502.T Takeda Pharmaceutical Company Limited | 4.22% |
| 22UA.DE BioNTech SE | 4.07% |
| CRSP CRISPR Therapeutics AG | 1.80% |
| NVAX NOVAVAX, INC. | 1.31% |
| 2595.HK GenFleet Therapeutics (Shanghai) Inc | 1.20% |
| NUVB Nuvation Bio Inc | 1.18% |
| VIR Vir Biotechnology Inc | 1.07% |
| ABCL ABCELLERA BIOLOGICS INC. | 1.06% |
Methodology breakdown computing — it will appear here on its own.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
IDNA (IDNA) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
Computing the full ratio and business-activity breakdown for IDNA — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 61.80 | NEUTRAL |
| Stochastic %K (14) | 78.32 | NEUTRAL |
| CCI (20) | 50.62 | NEUTRAL |
| Williams %R (14) | -21.68 | NEUTRAL |
| MACD (12,26,9) | -0.27 | SELL |
| ROC (10) | -0.50 | SELL |
| Momentum (10) | -0.20 | SELL |
| EMA (10) | 39.02 | BUY |
| SMA (10) | 38.99 | BUY |
| EMA (20) | 38.64 | BUY |
| SMA (20) | 39.50 | BUY |
| EMA (30) | 37.95 | BUY |
| SMA (30) | 38.24 | BUY |
| EMA (50) | 36.61 | BUY |
| SMA (50) | 36.04 | BUY |
| EMA (100) | 34.25 | BUY |
| SMA (100) | 33.18 | BUY |
| EMA (200) | 31.33 | BUY |
| SMA (200) | 30.85 | BUY |
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. The fund is non-diversified.
Background via Yahoo Finance — informational, not part of the verdict.
Average — needs more confirmation before sizing up
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 43 |
| ⏰ 4H | RANGING | 27 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.